Research Progress of Metal Anticancer Drugs
Pharmaceutics · 11.12.2023 · 15 (12) · 2750
DOI: 10.3390/pharmaceutics15122750 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 11.12.2023. Verfasst von Yun Bai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Inner Mongolia Key Laboratory of Environmental Chemistry, College of Chemistry and Enviromental Science, Inner Mongolia Normal University, 81 Zhaowud…. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Inner Mongolia, “Young Science and Technology Talents Program” (Leading Person) in Inner Mongolia Autonomous Region Colleges and Universities.
Abstract (Originalsprache)
Cancer treatments, including traditional chemotherapy, have failed to cure human malignancies. The main reasons for the failure of these treatments are the inevitable drug resistance and serious side effects. In clinical treatment, only 5 percent of the 50 percent of cancer patients who are able to receive conventional chemotherapy survive. Because of these factors, being able to develop a drug and treatment that can target only cancer cells without affecting normal cells remains a big challenge. Since the special properties of cisplatin in the treatment of malignant tumors were accidentally discovered in the last century, metal anticancer drugs have become a research hotspot. Metal anticancer drugs have unique pharmaceutical properties, such as ruthenium metal drugs with their high selectivity, low toxicity, easy absorption by tumor tissue, excretion, and so on. In recent years, efficient and low-toxicity metal antitumor complexes have been synthesized. In this paper, the scientific literature on platinum (Pt), ruthenium (Ru), iridium (Ir), gold (Au), and other anticancer complexes was reviewed by referring to a large amount of relevant literature at home and abroad.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Inner Mongolia Key Laboratory of Environmental Chemistry, College of Chemistry and Enviromental Science, Inner Mongolia Normal University, 81 Zhaowudalu, Hohhot 010022, China.
- College of Pharmacy, Inner Mongolia Medical University, Jinchuankaifaqu, Hohhot 010110, China.
- Inner Mongolia Key Laboratory of Carbon Nanomaterials, Nano Innovation Institute (NII), College of Chemistry and Materials Science, Inner Mongolia Minzu University, Tongliao 028000, China.
ORCID-Profile: Wenfeng Hai, Jun Ai
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Inner Mongolia
- “Young Science and Technology Talents Program” (Leading Person) in Inner Mongolia Autonomous Region Colleges and Universities
- Fundamental Research Funds for the Inner Mongolia Normal University, China
- Key Project of Natural Science Foundation of Inner Mongolia Autonomous Region
- Science and Technology Planning Project of Inner Mongolia Autonomous Region
- Program for Young Talents of Science and Technology in Universities of Inner Mongolia Autonomous Region
- Inner Mongolia Autonomous Region Science and Technology Plan
Zitieren
APA
Bai, Y., Aodeng, G., Ga, L., Hai, W., & Ai, J. (2023). Research Progress of Metal Anticancer Drugs. Pharmaceutics, 15(12), 2750. https://doi.org/10.3390/pharmaceutics15122750
Vancouver
Bai Y, Aodeng G, Ga L, Hai W, Ai J. Research Progress of Metal Anticancer Drugs. Pharmaceutics. 2023;15(12):2750. doi:10.3390/pharmaceutics15122750
BibTeX
@article{Bai2023,
author = {Bai, Yun and Aodeng, Gerile and Ga, Lu and Hai, Wenfeng and Ai, Jun},
title = {Research Progress of Metal Anticancer Drugs},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {12},
pages = {2750},
doi = {10.3390/pharmaceutics15122750}
}
EUVIMED